LivaNova (OTCMKTS: IMRSQ) and IMRIS (OTCMKTS:IMRSQ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.
This is a breakdown of current ratings and recommmendations for LivaNova and IMRIS, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
LivaNova has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, IMRIS has a beta of -3.41, meaning that its stock price is 441% less volatile than the S&P 500.
This table compares LivaNova and IMRIS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
86.9% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares LivaNova and IMRIS’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|LivaNova||$1.01 billion||5.99||-$25.08 million||$3.31||37.70|
IMRIS has lower revenue, but higher earnings than LivaNova.
LivaNova beats IMRIS on 8 of the 9 factors compared between the two stocks.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
IMRIS Company Profile
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.